Eric Terhaerdt appointed senior vice president of global development operations at Astellas

15 January 2015
eric-terhaerdt

Japanese drug major Astellas Pharma (TYO: 4503) has appointed Eric Terhaerdt as senior vice president of global development operations.

He will be responsible for establishing the global direction of the drug development operations of Astellas in the Netherlands and the USA and will work with Japan development operations to ensure global ops efficiency.

He will define development strategy and ensure the effective development of the company’s product portfolio.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical